Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse(TM) Injectable Hyaluronic Acid Gels
MWN-AI** Summary
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, has announced the launch of its innovative marketing campaign, “Drop the F Word,” in anticipation of the upcoming commercial launch of Evolysse™. This new line of injectable hyaluronic acid gels aims to transform the perception of aesthetic treatments by moving away from the outdated term “filler,” which has become synonymous with unnatural results and overfilled appearances. Recognizing a growing trend of “filler fatigue,” Evolus conducted extensive research to understand shifting consumer attitudes and subsequently decided to retire the term “filler” from its vernacular.
Evolysse™ is positioned as a collection of injectable gels tailored to provide long-lasting and natural-looking results for moderate to severe dynamic facial wrinkles, such as nasolabial folds. By utilizing advanced Cold-X™ technology, Evolus has significantly improved the manufacturing process, preserving the natural structure of the hyaluronic acid molecule to ensure desirable outcomes aligned with modern consumer expectations.
David Moatazedi, President and CEO of Evolus, emphasized the importance of evolving the conversation surrounding aesthetic treatments. With this campaign, Evolus is not just introducing a new product; they are also advocating for a broader cultural shift in the beauty industry that prioritizes personalization, education, and informed decision-making.
As Evolus prepares to redefine aesthetic injectables with Evolysse™, the “Drop the F Word” campaign embodies the company’s commitment to enhancing the aesthetics experience and meeting the demands of today’s beauty consumers. Through this initiative, Evolus aims to elevate industry standards and inspire a renewed appreciation for the innovative treatments available in the aesthetics market.
MWN-AI** Analysis
Evolus, Inc. (NASDAQ: EOLS) has entered a pivotal moment with the launch of its "Drop the F Word" campaign, coinciding with the introduction of Evolysse™, a new range of injectable hyaluronic acid (HA) gels. This initiative not only repositions the brand but also aims to redefine consumer perceptions surrounding aesthetic treatments, particularly the traditionally negative connotation attributed to “fillers.”
The campaign is strategically poised to combat "filler fatigue" by rebranding the category with a contemporary narrative that emphasizes personalization, education, and natural outcomes. This shift comes at a critical time when consumers are increasingly seeking results that enhance their natural beauty rather than produces an overfilled look. With the support of rigorous research identifying consumer fears associated with fillers, Evolus is making a proactive move to reshape the conversation surrounding injectables.
From an investment perspective, Evolus's venture into the redefinition of injectable aesthetics could significantly enhance its competitive edge in a growing market. The innovative Cold-X™ technology employed in Evolysse™ manufacturing suggests a commitment to quality and efficacy, strengthening the potential for sustained consumer trust and loyalty. As the aesthetics market continues to expand—with increasing demand for minimally invasive treatments—Evolus's ability to lead with education and innovation may help secure its standing as a market leader.
Moreover, the intersection of cultural sentiment towards aesthetics and advanced product offerings from Evolus could result in positive investor sentiment, especially as consumers increasingly prioritize confidence and informed decisions in beauty treatments. Analysts should monitor Evolus’s sales performance of Evolysse™ closely post-launch. With an adaptive marketing approach and an innovative product, Evolus is well-positioned for growth, making it an interesting potential buy for investors looking for opportunities within the beauty and wellness sectors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the launch of its bold new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of Evolysse ™ . Designed to challenge outdated perceptions and language in the aesthetics industry, the campaign introduces Evolysse ™ , a collection of injectable hyaluronic acid (HA) gels specifically designed to deliver long-lasting, natural-looking results for the treatment of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds.
The “Drop the F Word” campaign aims to reenergize the injectable HA category and address growing filler fatigue. Increasingly, consumers associate the term “filler” with unnatural results and an overfilled look, perceptions that no longer reflect the advancement of today’s products or consumer desires. In response, Evolus conducted in-depth research with customers and consumers to better understand these shifting attitudes. The insights were clear, “filler” is an outdated term and no longer serves the category. As a result, Evolus tested new ways to reframe the category and is introducing Evolysse ™ as a collection of injectable hyaluronic acid gels, removing “filler,” the “F word,” from its vernacular. This approach better reflects the innovation behind the collection and the results consumers expect today.
“As aesthetic treatments evolve, the conversation around them must evolve too,” said David Moatazedi, President and Chief Executive Officer of Evolus. “With the 'Drop the F Word' campaign, we’re pushing the industry forward, replacing the outdated term 'filler' with a more modern, meaningful conversation centered around personalization, education, and natural-looking results. Evolysse ™ isn’t just another filler, it’s the future of performance beauty.”
With the first breakthrough in HA technology in over a decade, Evolysse ™ marks a new chapter in aesthetic injectables, moving beyond the traditional concept of “fillers” and toward a new standard of personalized, natural-looking outcomes. Evolysse ™ is manufactured utilizing Cold-X ™ technology, an innovative manufacturing process designed to better preserve the natural structure of the HA molecule. The result is a collection of injectable HA gels that deliver natural-looking outcomes and align with the evolving expectations of today’s aesthetic consumers.
Through this initiative, Evolus is inviting patients, practitioners, and the broader beauty industry to rethink how aesthetic treatments are discussed, embraced, and delivered. The campaign also underscores the company’s broader mission and modern approach to elevate the aesthetics experience, prioritizing confidence and informed decision-making across all stakeholders.
With Evolysse ™ , Evolus is not only launching an innovative injectable HA collection but also leading a cultural shift in how beauty treatments are perceived. This campaign and product launch together represent a commitment to advancing performance beauty that reflects the expectations of today’s beauty consumer.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™ , a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com , and follow us on LinkedIn , X , Instagram or Facebook .
Jeuveau ® and Nuceiva ® , are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc.
Cold-X™ is a trademark of Symatese Group S.A.S.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415249207/en/
Evolus Contacts:
Investors:
Nareg Sagherian
Vice President, Head of Global Investor Relations and Corporate Communications
Tel: 248-202-9267
Email: ir@evolus.com
Media :
Email: media@evolus.com
FAQ**
How does Evolus Inc. EOLS plan to measure the success of its “Drop the F Word” campaign in changing perceptions within the aesthetic treatment market?
What specific innovations in the Cold-X™ technology are utilized in the Evolysse ™ product line to differentiate it from traditional injectables in the Evolus Inc. EOLS portfolio?
In what ways will the launch of Evolysse ™ contribute to Evolus Inc. EOLS's growth strategy and market positioning against competitors in the aesthetics industry?
How does Evolus Inc. EOLS intend to educate consumers and practitioners about the new branding and benefits of its Evolysse ™ products as part of the broader mission to reshape the aesthetics conversation?
**MWN-AI FAQ is based on asking OpenAI questions about Evolus Inc. (NASDAQ: EOLS).
NASDAQ: EOLS
EOLS Trading
-0.92% G/L:
$4.815 Last:
305,244 Volume:
$4.85 Open:
